[Pharmacological targeting of Mdm2: rationale and perspectives for radiosensitization].

[1]  Chong Li,et al.  D-peptide inhibitors of the p53–MDM2 interaction for targeted molecular therapy of malignant neoplasms , 2010, Proceedings of the National Academy of Sciences.

[2]  C. Rubbi,et al.  Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53 , 2010, British Journal of Cancer.

[3]  S. Miscia,et al.  Nutlins and ionizing radiation in cancer therapy. , 2010, Current pharmaceutical design.

[4]  Charles Giardina,et al.  DNA damage response to the Mdm2 inhibitor nutlin-3. , 2010, Biochemical pharmacology.

[5]  Peter M Fischer,et al.  Small-molecule inhibitors of MDM2 as new anticancer therapeutics. , 2010, Seminars in cancer biology.

[6]  H. Kagechika,et al.  Enhancement of imatinib-induced apoptosis of BCR/ABL-expressing cells by nutlin-3 through synergistic activation of the mitochondrial apoptotic pathway , 2010, Apoptosis.

[7]  Kaichun Wu,et al.  Inhibition of the p53–MDM2 interaction by adenovirus delivery of ribosomal protein L23 stabilizes p53 and induces cell cycle arrest and apoptosis in gastric cancer , 2009, The journal of gene medicine.

[8]  A. Azmi,et al.  An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals , 2009, Molecular Cancer.

[9]  F. Speleman,et al.  Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53. , 2009, Journal of the National Cancer Institute.

[10]  A. Gudkov,et al.  Cellular quiescence caused by the Mdm2 inhibitor Nutlin-3A , 2009, Cell cycle.

[11]  E. Moyal,et al.  [Angiogenic inhibitors and radiotherapy: from the concept to the clinical trial]. , 2009, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[12]  N. Magné,et al.  Concomitant chemo-radiotherapy in clinical trials: to promote step by step rational development. , 2009, Critical reviews in oncology/hematology.

[13]  W. El-Deiry,et al.  Targeting p53 for enhanced radio- and chemo-sensitivity , 2009, Apoptosis.

[14]  Richard J. Jones,et al.  Inhibition of the Human Double Minute (HDM)-2 E3 Ubiquitin Ligase Activates Different Programmed Cell Death (PCD) Pathways in Models of Non-Hodgkin Lymphoma (NHL) with Wild Type (wt) and Mutant (mut) p53 , 2008 .

[15]  Shaomeng Wang,et al.  Targeting the MDM2-p53 Interaction for Cancer Therapy , 2008, Clinical Cancer Research.

[16]  T. Berg.  Small-molecule inhibitors of protein-protein interactions. , 2008, Current opinion in drug discovery & development.

[17]  Alexander Dömling,et al.  Small molecular weight protein-protein interaction antagonists: an insurmountable challenge? , 2008, Current opinion in chemical biology.

[18]  M. Page,et al.  A first-in-class HDM2-inhibitor (JNJ-26854165) in phase I development shows potent activity against multiple myeloma (MM) cells in vitro and ex vivo , 2008 .

[19]  R. Stoyanova,et al.  Antisense MDM2 enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation in vitro and in vivo , 2008, The Prostate.

[20]  C. Blattner,et al.  JNJ-26854165 - a novel hdm2 antagonist in clinical development showing broad-spectrum preclinical antitumor activity against solid malignancies , 2008 .

[21]  Dajun Yang,et al.  Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition , 2008, Proceedings of the National Academy of Sciences.

[22]  D. Lane,et al.  Updates on p53: modulation of p53 degradation as a therapeutic approach , 2008, British Journal of Cancer.

[23]  P. Secchiero,et al.  The MDM-2 antagonist nutlin-3 promotes the maturation of acute myeloid leukemic blasts. , 2007, Neoplasia.

[24]  R. Stoyanova,et al.  Antisense-MDM2 sensitizes LNCaP prostate cancer cells to androgen deprivation, radiation, and the combination in vivo. , 2007, International journal of radiation oncology, biology, physics.

[25]  T. Jacks,et al.  Restoration of p53 function leads to tumour regression in vivo , 2007, Nature.

[26]  L. Mayo,et al.  Nutlin3 blocks vascular endothelial growth factor induction by preventing the interaction between hypoxia inducible factor 1alpha and Hdm2. , 2007, Cancer research.

[27]  Gerard I. Evan,et al.  Modeling the Therapeutic Efficacy of p53 Restoration in Tumors , 2006, Cell.

[28]  G. Evan,et al.  Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. , 2006, Cancer cell.

[29]  Xueliang Fang,et al.  Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategy. , 2006, Journal of medicinal chemistry.

[30]  D. Hallahan,et al.  Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2 , 2006, Molecular Cancer Therapeutics.

[31]  J. Coindre,et al.  Sarcomes des tissus mous : données moléculaires actuelles , 2006 .

[32]  D. Parks,et al.  Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo , 2006, Molecular Cancer Therapeutics.

[33]  Erwin G. Van Meir,et al.  Hypoxia inducible factor-1: a novel target for cancer therapy , 2005, Anti-cancer drugs.

[34]  F. Agani,et al.  Mdm2 and HIF‐1α interaction in tumor cells during hypoxia , 2005 .

[35]  C. M. Eischen,et al.  Mdm2 Binds to Nbs1 at Sites of DNA Damage and Regulates Double Strand Break Repair* , 2005, Journal of Biological Chemistry.

[36]  Maxwell D Cummings,et al.  1,4-Benzodiazepine-2,5-diones as small molecule antagonists of the HDM2-p53 interaction: discovery and SAR. , 2005, Bioorganic & medicinal chemistry letters.

[37]  A. Levine,et al.  MDM2 is a central node in the p53 pathway: 12 years and counting. , 2005, Current cancer drug targets.

[38]  Ruiwen Zhang,et al.  p53-independent activities of MDM2 and their relevance to cancer therapy. , 2005, Current cancer drug targets.

[39]  Mi-Ock Lee,et al.  Novel Function of Orphan Nuclear Receptor Nur77 in Stabilizing Hypoxia-inducible Factor-1α* , 2004, Journal of Biological Chemistry.

[40]  F. Agani,et al.  Vascular Endothelial Growth Factor Transcriptional Activation Is Mediated by Hypoxia-inducible Factor 1α, HDM2, and p70S6K1 in Response to Phosphatidylinositol 3-Kinase/AKT Signaling* , 2004, Journal of Biological Chemistry.

[41]  Donald J Abraham,et al.  A nonpeptidic sulfonamide inhibits the p53-mdm2 interaction and activates p53-dependent transcription in mdm2-overexpressing cells. , 2004, Journal of medicinal chemistry.

[42]  R. Hill,et al.  Hypoxia Enhances Metastatic Efficiency by Up-Regulating Mdm2 in KHT Cells and Increasing Resistance to Apoptosis , 2004, Cancer Research.

[43]  M. Ashcroft,et al.  Growth Factor-Mediated Induction of HDM2 Positively Regulates Hypoxia-Inducible Factor 1α Expression , 2004, Molecular and Cellular Biology.

[44]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[45]  S. Lowe,et al.  Control of apoptosis by p53 , 2003, Oncogene.

[46]  M. Caligiuri,et al.  BCR/ABL activates mdm2 mRNA translation via the La antigen. , 2003, Cancer cell.

[47]  M. Rolfe,et al.  Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[48]  Xin Lu,et al.  Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.

[49]  H. Taubert,et al.  Transfection with mdm2-antisense or wtp53 results in radiosensitization and an increased apoptosis of a soft tissue sarcoma cell line. , 2001, Anticancer research.

[50]  S. T. Kim,et al.  ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. , 2001, Genes & development.

[51]  M. Ivan,et al.  HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2 Sensing , 2001, Science.

[52]  C. Renner,et al.  Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. , 2001, Biochemistry.

[53]  M. Oren,et al.  Mdm2: The Ups and Downs , 1999, Molecular medicine.

[54]  P. Verrelle,et al.  Modulation de la réponse cellulaire aux radiations ionisantes vers de nouvelles cibles moléculaires , 1997 .

[55]  G. Lozano,et al.  Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. , 1997, Genes & development.

[56]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[57]  D. Lane,et al.  Identification of novel mdm2 binding peptides by phage display. , 1996, Oncogene.

[58]  A. Levine,et al.  Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.

[59]  A. Levine,et al.  mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein , 1996, Molecular and cellular biology.

[60]  K. Dameron,et al.  Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. , 1994, Science.

[61]  M. Oren,et al.  Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. , 1994, Genes & development.

[62]  A. Levine,et al.  Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. , 1994, Genes & development.

[63]  S. Lowe,et al.  Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas , 2011, Nature.

[64]  M. Andreeff,et al.  linical Development Novel Tryptamine Derivative JNJ-26854165 Induces-Type p 53-and E 2 F 1-Mediated Apoptosis in Ther te Myeloid and Lymphoid Leukemias , 2010 .

[65]  宮地 充.  Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells , 2010 .

[66]  G. Wahl,et al.  Increased Radioresistance and Accelerated B Cell LymphomasinMicewithMdmxMutationsthatPrevent , 2009 .

[67]  V. Favaudon,et al.  [Determinants and predictive factors of tumour radiosensitivity]. , 2008, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[68]  S. Sebti,et al.  Protein – Protein Interactions Terphenyl-Based Helical Mimetics That Disrupt the p 53 / HDM 2 Interaction * * , 2007 .

[69]  P. Meltzer,et al.  Advances in Brief p 53 Mutation and MDM 2 Amplification in Human Soft Tissue Sarcomas 1 , 2006 .

[70]  P. Meltzer.  MDM 2 and p 53 : a Question of Balance , 2005 .

[71]  A. Levine,et al.  A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans , 2004, Cell.

[72]  M. Roussel,et al.  The RING Domain of Mdm 2 Can Inhibit Cell Proliferation 1 , 2002 .

[73]  S. Deb.  Function and dysfunction of the human oncoprotein MDM2. , 2002, Frontiers in bioscience : a journal and virtual library.

[74]  H. Findley,et al.  Incidence and prognostic significance of MDM2 oncoprotein overexpression in relapsed childhood acute lymphoblastic leukemia , 2000, Leukemia.

[75]  B. Quesnel,et al.  MDM2 gene amplification in human breast cancer. , 1994, European journal of cancer.